Table 2B.
Baseline demographic and clinical characteristics of older and younger patients with type 2 diabetes mellitus from a study of saxagliptin 5 mg as initial combination therapy with metformin vs metformin monotherapy22
| Characteristic | Age ≥ 65 years
|
Age < 65 years
|
||
|---|---|---|---|---|
| SAXA + MET n = 33 | MET n = 36 | SAXA + MET n = 287 | MET n = 292 | |
| Age (y), mean (SD) | 68.6 (2.8) | 69.6 (4.0) | 50.0 (9.2) | 49.6 (9.2) |
| Gender, n (%) | ||||
| Male | 10 (30.3) | 14 (38.9) | 155 (54.0) | 149 (51.0) |
| Female | 23 (69.7) | 22 (61.1) | 132 (46.0) | 143 (49.0) |
| Race, n (%) | ||||
| White | 30 (90.9) | 33 (91.7) | 216 (75.3) | 218 (74.7) |
| Asian | 1 (3.0) | 1 (2.8) | 50 (17.4) | 51 (17.5) |
| Black/African American | 0 | 0 | 7 (2.4) | 4 (1.4) |
| Other | 2 (6.1) | 2 (5.6) | 14 (4.9) | 19 (6.5) |
| Weight (kg), mean (SD) | 79.6 (12.9) | 79.4 (16.0) | 82.3 (16.6) | 83.2 (17.7) |
| BMI (kg/m2), mean (SD) | 30.1 (3.6) | 29.4 (3.9) | 29.9 (4.5) | 30.3 (5.0) |
| T2DM duration (y), mean (SD) | 0.8 (1.7) | 1.4 (1.9) | 2.1 (3.8) | 1.8 (3.3) |
| HbA1c (%), mean (SD) | 9.2 (1.4) | 8.9 (1.1) | 9.4 (1.2) | 9.5 (1.3) |
| <8.0%, n (%) | 5 (15.2) | 5 (13.9) | 26 (9.1) | 32 (11.0) |
| ≥8.0% to <9.0%, n (%) | 12 (36.4) | 17 (47.2) | 80 (27.9) | 81 (27.7) |
| ≥9.0%, n (%) | 16 (48.5) | 14 (38.9) | 179 (62.4) | 178 (61.0) |
| FPG (mg/dL), mean (SD) | 207.2 (57.3) | 192.5 (56.0) | 197.9 (56.5) | 198.9 (59.0) |
| CrCl (mL/min), mean (SD) | 82.9 (18.09) | 81.9 (20.28) | 120.2 (36.40) | 119.1 (37.43) |
| Number of concomitant medications*, n (%) | ||||
| 0 | 5 (15.2) | 8 (22.2) | 82 (28.6) | 57 (19.5) |
| 1 | 5 (15.2) | 5 (13.9) | 71 (24.7) | 78 (26.7) |
| 2 | 7 (21.2) | 7 (19.4) | 58 (20.2) | 60 (20.5) |
| 3 | 6 (18.2) | 8 (22.2) | 34 (11.8) | 36 (12.3) |
| 4 | 4 (12.1) | 2 (5.6) | 8 (2.8) | 27 (9.2) |
| ≥5 | 6 (18.2) | 6 (16.7) | 34 (11.8) | 34 (11.6) |
Notes:
*
Medication taken during lead-in or double-blind treatment; could include diabetes or nondiabetes medications (eg, antihypertensive medication, analgesics/antipyretics, antihyperglycemic medication).
Abbreviations: BMI, body mass index; CrCl, creatinine clearance; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; MET, metformin; PBO, placebo; SAXA, saxagliptin; SD, standard deviation; T2DM, type 2 diabetes mellitus.